Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts.
Clin Infect Dis
; 73(9): e2908-e2917, 2021 11 02.
Статья
в английский
| MEDLINE | ID: covidwho-1501002
ABSTRACT
BACKGROUND:
We projected the clinical and economic impact of alternative testing strategies on coronavirus disease 2019 (COVID-19) incidence and mortality in Massachusetts using a microsimulation model.METHODS:
We compared 4 testing strategies (1) hospitalized polymerase chain reaction (PCR) testing only for patients with severe/critical symptoms warranting hospitalization; (2) symptomatic PCR for any COVID-19-consistent symptoms, with self-isolation if positive; (3) symptomaticâ +â asymptomatic once symptomatic and 1-time PCR for the entire population; and (4) symptomaticâ +â asymptomatic monthly symptomatic with monthly retesting for the entire population. We examined effective reproduction numbers (Re = 0.9-2.0) at which policy conclusions would change. We assumed homogeneous mixing among the Massachusetts population (excluding those residing in long-term care facilities). We used published data on disease progression and mortality, transmission, PCR sensitivity/specificity (70%/100%), and costs. Model-projected outcomes included infections, deaths, tests performed, hospital-days, and costs over 180 days, as well as incremental cost-effectiveness ratios (ICERs, $/quality-adjusted life-year [QALY]).RESULTS:
At Re = 0.9, symptomaticâ +â asymptomatic monthly vs hospitalized resulted in a 64% reduction in infections and a 46% reduction in deaths, but required >66-fold more tests/day with 5-fold higher costs. Symptomaticâ +â asymptomatic monthly had an ICER <$100â 000/QALY only when Re ≥1.6; when test cost was ≤$3, every 14-day testing was cost-effective at all Re examined.CONCLUSIONS:
Testing people with any COVID-19-consistent symptoms would be cost-saving compared to testing only those whose symptoms warrant hospital care. Expanding PCR testing to asymptomatic people would decrease infections, deaths, and hospitalizations. Despite modest sensitivity, low-cost, repeat screening of the entire population could be cost-effective in all epidemic settings.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Тип исследования:
Экспериментальные исследования
/
Наблюдательное исследование
/
Прогностическое исследование
Темы:
Длинный Ковид
Язык:
английский
Журнал:
Clin Infect Dis
Тематика журнала:
Инфекционные болезни
Год:
2021
Тип:
Статья
Аффилированная страна:
Cid
Документы, близкие по теме
MEDLINE
...
LILACS
LIS